Call for NICE to reverse decision to reject novel osteoporosis drug

摘要

Clinicians are calling for the National Institute for Health and Care Excellence (NICE) to reconsider its provisional decision not to recommend use of the first new osteoporosis medication it has considered for more than a decade. Romosozumab, which works by both inducing new bone formation and reducing bone breakdown, is one of only two treatments licensed by the Medicines and Healthcare Regulatory Agency (MHRA) that stimulates new bone formation. It is already approved for use in Scotland and Northern Ireland, as well as parts of Europe.